Carl Thys

LiGalli BV is a Dutch company that focuses on women's health by providing personalized treatment through their innovative product, the MedRing. LiGalli is based in The Hague, NL, and aims to enhance the quality of life and care of women. The MedRing is a vaginal ring that is equipped with smart technology and biosensors to monitor and record data. It is clinically proven to successfully deliver a range of drugs through the vaginal mucosa and lasts for 28 days. The joint venture company was founded in 2014 by Willem de Laat, who has been the CEO since then.

LiGalli BV is a Dutch company that focuses on women's health by providing personalized treatment through their innovative product, the MedRing. LiGalli is based in The Hague, NL, and aims to enhance the quality of life and care of women. The MedRing is a vaginal ring that is equipped with smart technology and biosensors to monitor and record data. It is clinically proven to successfully deliver a range of drugs through the vaginal mucosa and lasts for 28 days. The joint venture company was founded in 2014 by Willem de Laat, who has been the CEO since then.

LiGalli BV is a Dutch company that focuses on women's health by providing personalized treatment through their innovative product, the MedRing. LiGalli is based in The Hague, NL, and aims to enhance the quality of life and care of women. The MedRing is a vaginal ring that is equipped with smart technology and biosensors to monitor and record data. It is clinically proven to successfully deliver a range of drugs through the vaginal mucosa and lasts for 28 days. The joint venture company was founded in 2014 by Willem de Laat, who has been the CEO since then.

LiGalli BV is a Dutch company that focuses on women's health by providing personalized treatment through their innovative product, the MedRing. LiGalli is based in The Hague, NL, and aims to enhance the quality of life and care of women. The MedRing is a vaginal ring that is equipped with smart technology and biosensors to monitor and record data. It is clinically proven to successfully deliver a range of drugs through the vaginal mucosa and lasts for 28 days. The joint venture company was founded in 2014 by Willem de Laat, who has been the CEO since then.